Compare FA & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FA | ADPT |
|---|---|---|
| Founded | 2003 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.7B |
| IPO Year | 2021 | 2019 |
| Metric | FA | ADPT |
|---|---|---|
| Price | $17.82 | $20.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | $15.67 | ★ $17.78 |
| AVG Volume (30 Days) | 1.8M | ★ 3.4M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.97 | 63.89 |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $1,574,389,000.00 | $276,976,000.00 |
| Revenue This Year | $8.42 | $3.98 |
| Revenue Next Year | $7.26 | $22.72 |
| P/E Ratio | $1,676.00 | ★ N/A |
| Revenue Growth | ★ 83.02 | 54.77 |
| 52 Week Low | $8.82 | $9.96 |
| 52 Week High | $18.55 | $20.76 |
| Indicator | FA | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 66.92 | 71.02 |
| Support Level | $14.07 | $15.08 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.72 | 1.33 |
| MACD | 0.02 | 0.28 |
| Stochastic Oscillator | 89.92 | 93.68 |
First Advantage Corp is a provider of software and data in the Human Resources technology industry. The company provides end-to-end identity solutions, criminal background screening, credential verifications, drug and health screening, and continuous risk monitoring. It combines AI-powered proprietary technology platforms with proprietary data, primary source data, and third-party data. Its reportable segments are First Advantage Americas, First Advantage International, and Sterling. The company generates maximum revenue from the Sterling segment, which provides similar services as compared to First Advantage's Americas and International segments on a global basis. Geographically, the company generates the majority of its revenue from the United States.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.